MOGLYNET

PhD programme in DRUG DISCOVERY AND DEVELOPMENT 2015-2019

Scholarship Programme Promoting Institutional Cooperation and Mobility for 12 early stage researchers

Mission

The mission of MoGlyNet is to define a joint doctorate educational training model in Drug Discovery and Development where Academia and Industry, supported by other institutions/organizations, join their forces for:

• Creating a common platform of knowledge and language for 12 early stage researchers(ESR) working in the Drug Discovery and Development area aiming to convey complementary Pharma-skills
• Exploiting this platform to train a new generation of cutting-edge researchers and professionals highly attractive for employment by the European Pharma-industry and regulatory authorities
• Establishing structures for long-term cooperation, strengthening the relationships among the leading Universities and Pharma-enterprises and to continuously develop the research training platform that European industry relies on

Doctorate Courses/Schools

• University of Milan: Pharmaceutical Sciences
• University of Milan: Experimental and Clinical Pharmacological Sciences
• University of Aberdeen: Graduate School in Life Sciences and Medicine
• University of Antwerp: Antwerp Doctoral School
• University of Barcelona Doctoral School
• University of Leiden: Graduate School of Leiden University Medical Center

Research project

Atherosclerotic cardiovascular disease is the major cause of death in the western world. Thanks to cholesterol-lowering drugs, the lifespan and wellbeing of patients have been significantly improved. However, a large group of patients does not fully benefit from current lipid-lowering strategies.
Our multidisciplinary approach is focused on counteracting neovessel formation to prevent plaque rupture and its cardiovascular complications, thus leading to a more effective therapy for atherosclerosis.

Research methodology and approach

The MoGlyNet consortium is strongly multidisciplinary and takes advantage of a number of different state-of-the-art technologies and methodologies:

• Computational chemistry and synthesis
• Bioanalytics and biophysics
• In vitro and in vivobiological evaluation
• Imaging
• Metabolomic and Proteomic studies
• Oxidative stress studies

Beneficiaries

• University of Milan (Pharmaceutical Sciences and Pharmacological and Biomolecular Sciences Departments), Italy – Coordinating University
• University of Aberdeen (Institute of Medical Sciences, School of Medicine, Medical Sciences and Nutrition), UK
• University of Antwerp (Laboratory of Physiopharmacology), Belgium
• University of Barcelona (Department of Biochemistry and Molecular Biology), Spain
• Leiden University Medical Center (Department of Surgery and Einthoven Laboratory for Experimental Vascular Medicine), The Netherlands

Partners and Associations

• Bayer HealthCare Manufacturing S.r.l., Italy
• Biomax Informatics AG, Germany
• HistoGeneX N.V., Belgium
• KemoTech Srl, Italy
• Linkcare Health Services, Spain
• Ingenus Pharmaceutical GmbH, Switzerland
• PPD Italy srl, Italy
• EIPG (European Industrial Pharmacists Group)
• EAS (European Atherosclerosis Society)
• EDQM (European Directorate for the Quality of Medicines

CONTACTS
secretary@moglynet.com
Tel. +390250314471
Fax +390250314476

Flyer

Website

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 67552